Macrolide exposure during first trimester not linked to congenital malformations, study finds
A new study published in the journal of PLOS Medicine showed that for the majority of individual major congenital malformations (MCMs), exposure to macrolides during the first trimester is not significantly linked to an elevated risk, which is comforting.
Because macrolides may penetrate the placenta, even at a low rate, the risk of severe congenital malformations linked to exposure to them during pregnancy is usually a cause for worry. Despite being one of the most often given antibiotics for expectant mothers, there is still contradictory information about the safety of macrolides for the fetus. With a focus on certain MCM subtypes, Anh Tran and team sought to assess the risk of major congenital malformations following first-trimester exposure to macrolides as opposed to amoxicillin.
Data from the Mother-Child EPI-MERES Register, which is housed inside the French Health Data System (SNDS), was utilized in this countrywide cohort research. Included were pregnancies associated with their singleton live-born children between January 1, 2010, and December 31, 2020. Pregnancies with one or more prescriptions written for systemic macrolides (erythromycin, roxithromycin, spiramycin, clarithromycin, josamycin, and azithromycin) during the first trimester were included in the macrolide exposure group.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.